# A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

> **NCT04209855** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 453 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab Soravtansine
- **DRUG:** Paclitaxel
- **DRUG:** Topotecan
- **DRUG:** Pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT04209855
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-31
- **Primary completion:** 2023-03-06
- **Final completion:** 2024-10-29
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209855, "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04209855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*